FGF19 and its analog Aldafermin cooperate with MYC to induce aggressive hepatocarcinogenesis - Archive ouverte HAL Accéder directement au contenu
Pré-Publication, Document De Travail Année : 2023

FGF19 and its analog Aldafermin cooperate with MYC to induce aggressive hepatocarcinogenesis

Pauline Marie
  • Fonction : Auteur
Arnaud Polizzi
Benjamin Riviere
  • Fonction : Auteur
Herve Guillou
Eric Assenat
  • Fonction : Auteur
Urszula Hibner

Résumé

FGF19 hormone has pleiotropic metabolic functions, notably the modulation of insulin sensitivity, glucose/lipid metabolism and energy homeostasis. On top of its physiological metabolic role, FGF19 has been identified as a potentially targetable oncogenic driver, notably in hepatocellular carcinoma (HCC). Nevertheless, FGF19 remained an attractive candidate for treatment of metabolic disease, prompting the development of analogs uncoupling its metabolic and tumor-promoting activities. Using pre-clinical mice models of somatic mutation driven HCC, we assessed the oncogenicity of FGF19 in combination with frequent HCC tumorigenic alterations: p53 inactivation, CTNNB1 mutation, CCND1 or MYC overexpression. Our data revealed a strong oncogenic cooperation between FGF19 and MYC. Most importantly, we show that this oncogenic synergy is conserved with a FGF19-analog Aldafermin (NGM282), designed to solely mimic the hormone's metabolic functions. In particular, even a short systemic treatment with recombinant proteins triggered rapid appearance of proliferative foci of MYC-expressing hepatocytes. The fact that FGF19 analog Aldafermin is not fully devoid of the hormone's oncogenic properties raises concerns in the context of its potential use for patients with damaged, mutation-prone liver.
Fichier principal
Vignette du fichier
2023 Ursic-Bedoya, Desandre biorxiv.pdf (754.53 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-04209842 , version 1 (18-09-2023)

Licence

Paternité - Pas d'utilisation commerciale - Pas de modification

Identifiants

Citer

Jose Ursic-Bedoya, Guillaume Desandre, Carine Chavey, Pauline Marie, Arnaud Polizzi, et al.. FGF19 and its analog Aldafermin cooperate with MYC to induce aggressive hepatocarcinogenesis. 2023. ⟨hal-04209842⟩
6 Consultations
68 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More